XPhyto Therapeutics Corp. (“XPhyto”) is a diversified bioscience company with strategic assets and investments in the field of rapid pathogen screening systems and next generation drug delivery, as well as medical cannabis opportunities focused on emerging European markets. Through its 100% owned subsidiaries and exclusive development and commercialization agreements, XPhyto is pursuing clinical programs for the transdermal and dissolvable oral delivery of conventional and cannabis based therapeutics for neurological applications, as well as rapid dissolvable oral biosensor and lateral flow assay-based screening tests for dental health applications and high-risk pandemic threats such as COVID-19, H1N1 (swine flu) and H5N1 (avian flu).